276 related articles for article (PubMed ID: 25342901)
1. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
[TBL] [Abstract][Full Text] [Related]
2. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
3. Regulating nanomedicine - can the FDA handle it?
Bawa R
Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
[TBL] [Abstract][Full Text] [Related]
4. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
5. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
6. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan.
Chang LC; Kang JJ; Gau CS
Regul Toxicol Pharmacol; 2015 Dec; 73(3):947-52. PubMed ID: 26387930
[TBL] [Abstract][Full Text] [Related]
7. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.
Gaspar R
Nanomedicine (Lond); 2007 Apr; 2(2):143-7. PubMed ID: 17716116
[No Abstract] [Full Text] [Related]
8. Nanomedicines: From Bench to Bedside and Beyond.
Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
[TBL] [Abstract][Full Text] [Related]
9. Beyond biotechnology: FDA regulation of nanomedicine.
Miller J
Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335
[TBL] [Abstract][Full Text] [Related]
10. Issues and concerns in nanotech product development and its commercialization.
Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I
J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600
[TBL] [Abstract][Full Text] [Related]
11. The impact of effective patents on future innovations in nanomedicine.
Bosetti R; Vereeck L
Pharm Pat Anal; 2012 Mar; 1(1):37-43. PubMed ID: 24236712
[TBL] [Abstract][Full Text] [Related]
12. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
13. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
14. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
[TBL] [Abstract][Full Text] [Related]
15. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
Mühlebach S; Borchard G; Yildiz S
Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines: addressing the scientific and regulatory gap.
Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
[TBL] [Abstract][Full Text] [Related]
17. Unique benefits of nanotechnology to drug delivery and diagnostics.
McNeil SE
Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949
[TBL] [Abstract][Full Text] [Related]
18. [Development trend of nanomedicines].
Kato K
Yakugaku Zasshi; 2013; 133(1):43-51. PubMed ID: 23292019
[TBL] [Abstract][Full Text] [Related]
19. European Commission-supported development of targeted nanomedicines: did MediTrans make a difference?
Storm G; Aime S
Ther Deliv; 2011 Jul; 2(7):861-4. PubMed ID: 22833900
[TBL] [Abstract][Full Text] [Related]
20. Policy challenges of nanomedicine for Australia's PBS.
Faunce TA
Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
